ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 0662 • ACR Convergence 2024

    Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial

    Eric Morand1, Cristina Arriens2, Laura Geraldino3, Ann E. Clarke4, Samantha Pomponi5, Coburn Hobar5, Thomas Wegman6, Ravi Koti5, Subhashis Banerjee5 and Ronald Van Vollenhoven7, 1School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 2Department of Arthritis and Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, 4Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5Bristol Myers Squibb, Princeton, NJ, 6Bristol Myers Squibb, Beaver Falls, PA, 7Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…
  • Abstract Number: 0975 • ACR Convergence 2024

    Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica

    Sebastian E. Sattui1, FRANK HARTMUT DR. BUTTGEREIT2, Merav Lidar3, Kerri Ford4, Stefano Fiore5, Lita Araujo4, Timothy Beukelman6, Fenglong Xie7 and Jeffrey Curtis8, 1University of Pittsburgh, Pittsburgh, PA, 2Charité University Medicine Berlin, Berlin, Germany, 3Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, 4Sanofi, Cambridge, MA, 5Sanofi, Bridgewater, NJ, 6Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL, 8The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
  • Abstract Number: 1244 • ACR Convergence 2024

    Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO

    Alain Lescoat1, Yen Chen2, Rosemary Gedert2, Neda Kortam2, Nadia Vann2, David Cella3, Sara Shaunfield4, Susan Murphy5 and Dinesh Khanna2, 1CHU Rennes - University Rennes 1, Rennes, France, 2University of Michigan, Ann Arbor, MI, 3Northwestern University, Chicago, IL, 4Northwestern University, Chicago, 5University of Michigan, Plymouth, MI

    Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures to assess symptoms that…
  • Abstract Number: 1552 • ACR Convergence 2024

    Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial

    Ronald Van Vollenhoven1, Joseph Merola2, Kathryn H. Dao3, Piotr Leszczynski4, Marilyn Pike5, Samantha Pomponi6, Coburn Hobar6, Matthew J. Colombo6, Ravi Koti6, Subhashis Banerjee6, Thomas Wegman7 and Eric Morand8, 1Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 2UT Southwestern Medical Center, Newton, MA, 3Department of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, 4Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland, 5Rheumatology, MedPharm Consulting, Inc., Raleigh, NC, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Beaver Falls, PA, 8School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…
  • Abstract Number: 2056 • ACR Convergence 2024

    Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial

    Kevin Winthrop1, Joseph Merola2, Akimichi Morita3, Diamant Thaçi4, Jianzhong Zhang5, Aditi Basu Ba6, Ian M. Catlett7, John Schwarz6 and Yi Luo6, 1School of Medicine, Oregon Health and Science University, Portland, OR, 2UT Southwestern Medical Center, Newton, MA, 3Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 4Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, 5Department of Dermatology, Peking University People’s Hospital, Beijing, China, 6Bristol Myers Squibb, Princeton, 7Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
  • Abstract Number: 2283 • ACR Convergence 2024

    Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry

    Joshua Baker1, Kristi Mizelle2, Wassim Saikali3, Page Moore4, Hyung-Joo Kang4, David Gruben5, Ahmed Shelbaya6, Lori Stockert7 and Jacqueline O'Brien4, 1Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 2TPMG Rheumatology, Newport News, VA, 3Rheumatology and Pulmonary Clinic, Beckley, WV, 4CorEvitas, LLC, Waltham, MA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Janus kinase inhibitors (JAKi) are a widely acceptable drug class in the treatment of RA. However, real-world data on the patterns of JAKi use and…
  • Abstract Number: 2640 • ACR Convergence 2024

    Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis

    Alexander Wu1, Arianna Zhang2, Yujia Guo1, Jialing Liu1, Donghan Yang1, Lourdes Perez Chada3, Alexis Ogdie4, Jose Scher5 and Joseph Merola6, 1University of Texas Southwestern Medical Center, Dallas, 2Brigham and Women's Hospital, Boston, MA, 3Harvard Medical School, Wayland, MA, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5New York University School of Medicine, New York, NY, 6UT Southwestern Medical Center, Newton, MA

    Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
  • Abstract Number: 0325 • ACR Convergence 2024

    The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis

    Pitchaporn Yingchoncharoen1, Nattanicha Chaisrimaneepan2, Jerapas Thongpiya1, Pojsakorn Danpanichkul1 and Yanint Raksadawan3, 1Texas Tech Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock, TX, 3Weiss Memorial Hospital, Chicago, IL

    Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
  • Abstract Number: 0557 • ACR Convergence 2024

    What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

    Marco Garrido-Cumbrera1, Victoria Navarro Compán2, Fernando Andres Sommerfleck3, Christine Bundy4, Souzi Makri5, José Correa-Fernández6, Shashank Akerkar7, Jo Lowe8, Elie Karam9 and Denis Poddubnyy10, 1Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain / Spanish Federation of Spondyloarthritis Patient Associations (CEADE), Madrid, Spain, Seville, Spain, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3Sanatorio Julio Mendez, Buenos Aires, Argentina, 4Cardiff University, Cardiff, UK, Cardiff, United Kingdom, 5Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, Nicosia, Cyprus, 6Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, 7Mumbai Arthritis Clinic, Mumbai, India, Mumbai, India, 8Axial Spondyloarthritis International Federation, London, United Kingdom, 9Canadian Spondylitis Association (CSA), Toronto, Canada, Toronto, Canada, 10Charite-Universitatsmedizin Berlin, Berlin, Germany

    Background/Purpose: Severe pain in patients with axial spondyloarthritis (axSpA) can cause deterioration in their physical and mental health. The aim is to investigate factors associated…
  • Abstract Number: 0679 • ACR Convergence 2024

    Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study

    Rachel Wallwork1, Haomin Hu2, Ami Shah3, Laura Hummers4, John Pauling5, Victoria Flower6, Bambang Parmanto2, Andi Saptono2 and Robyn Domsic7, 1Johns Hopkins University, Towson, MD, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 4Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 5North Bristol NHS Trust, Bristol, United Kingdom, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene.  Despite…
  • Abstract Number: 1005 • ACR Convergence 2024

    Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib

    Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral

    Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
  • Abstract Number: 1300 • ACR Convergence 2024

    Tackling Rheumatology Workforce Shortages with a Case-Based Primary Care Rheumatology Curriculum

    Diego Cabrera1, Betty Hsiao2 and Fotios Koumpouras1, 1Yale School of Medicine, New Haven, CT, 2Yale-New Haven Medical Center, New Haven, CT

    Background/Purpose: Rheumatology is facing an imminent workforce shortage adversely affecting patients’ access to care. Primary care physicians are key stakeholders in the early evaluation and…
  • Abstract Number: 1554 • ACR Convergence 2024

    Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials

    Karen Costenbader1, Joan Merrill2, Marta Mosca3, Holly Quasny4, Christine Henning5, Steven Bloom6, Julia Harris6, Ciara O’Shea7, Tatsuya Atsumi8 and Ronald van Vollenhoven9, 1Brigham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Boston, MA, 2Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, 3University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 4GSK, Clinical Sciences, Durham, NC, 5GSK, Global Medical Affairs, Durham, NC, 6GSK, Immunology Biostatistics, Brentford, United Kingdom, 7GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 9Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands

    Background/Purpose: There are benefits of early treatment for autoimmune diseases; however, data are not available for patients (pts) with SLE as there is no definition…
  • Abstract Number: 2062 • ACR Convergence 2024

    Performance of the Patient Self-Assessment Tools for Cutaneous Dermatomyositis: Patient CDASI and Rash Mapping

    Nantakarn Pongtarakulpanit1, Tanya Chandra1, shiri keret2, Eugenia Gkiaouraki3, Vladimir Liarski1, Dana Ascherman3, Siamak Mogahadam1, Chester Oddis1 and Rohit Aggarwal4, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a current standard for evaluating rashes in Dermatomyositis (DM). However, there is increasing emphasis on…
  • Abstract Number: 2291 • ACR Convergence 2024

    The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease

    Dana DiRenzo1, Chadwick Johr1, Nora Sandorfi1, Sara McCoy2 and Thomas Grader-Beck3, 1University of Pennsylvania, Philadelphia, PA, 2University of Wisconsin, Middleton, WI, 3Johns Hopkins, Baltimore, MD

    Background/Purpose: Historically, Heath Related Quality of Life (HRQL) in Sjogren’s Disease (SjD) has been measured by the EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI), which…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology